Introduction {#S1}
============

Bladder contractile dysfunctions, such as overactive bladder (OAB) and underactive bladder (UAB), are common lower urinary tract dysfunctions that lower the overall quality of life in people living with it ([@B26]; [@B17]), heightens the likelihood of developing depression and anxiety, as well as increase healthcare usage ([@B39]). Despite extensive research investigating the mechanisms that potentially mediate bladder contractions, the cause and development of many lower urinary tract dysfunctions are poorly understood. Bladder contractions are under the control of the parasympathetic nervous system ([@B18]) and mediated by the release of acetylcholine that acts upon the M2 and M3 muscarinic receptors found in the detrusor smooth muscle ([@B27]; [@B56]). It has been recognized that the urothelium, which lines the lumen of the bladder, is capable of responding to mechanical, chemical and thermal stimuli ([@B9]; [@B58], [@B60]). Furthermore, it is capable of releasing several signaling molecules in response to stretch, including acetylcholine ([@B43]) ATP and nitric oxide ([@B21]; [@B23]) that are involved in the modulation of the micturition reflex. Myofibroblasts (also referred to as interstitial cells) found in the underlying lamina propria are thought to be involved in modulating bladder behavior by amplifying sensory responses to stretch occurring during the filling phase ([@B22]). Therefore, the involvement of the urothelium and the underlying lamina propria should be considered as potential contributors to bladder contractile pathology.

Prostaglandins have been suggested to be involved in the modulation of bladder function for decades. They are synthesized from arachidonic acid that is released from the cell membrane via the hydrolysis of the SN-2 bond by the phospholipase A2 enzyme (PLA2) ([@B15]). Prostaglandins can also be produced locally within the U&LP and smooth muscle layers in the human urinary bladder ([@B4]; [@B29]). Two cyclooxygenase isoforms COX-1 and COX-2 metabolize arachidonic acid into PGH~2~, which is subsequently converted into five primary prostaglandins via their respective synthases: PGE~2~, PGD~2~, PGF~2α~, PGI~2~ and TXA~2~ ([@B64]). These signaling molecules exert their function through the stimulation of nine specific G-protein coupled receptors (GPCRs): EP1--EP4, DP1, DP2, FP2, IP, and TP, respectively. Both COX-1 and COX-2 are expressed within the bladder wall ([@B19], [@B20]) specifically on the urothelium, lamina propria and on the surface of the inner muscle bundles of the detrusor. COX-1 is predominately expressed in the basal and intermediate layers of the urothelium and on the interstitial cells located in the lamina propria, indicating that these cells are capable of respond to prostaglandins ([@B20]). The production of prostaglandins differs between species. For example, in the rat bladder, PGI~2~ is the major prostaglandin produced ([@B28]), whereas in the rabbit bladder it is PGE~2~ ([@B34]). In the human bladder, the primary prostaglandins synthesized are PGI~2~, followed by PGE~2,~ PGF~2α~, and TXA~2~ ([@B28]; [@B37]). However, there are significant differences in the bladder contractile responses between species for the different prostaglandin receptor subtypes ([@B53]).

Studies involving human detrusor have shown that the release of prostaglandins has direct influences on the micturition reflex ([@B10]; [@B7]). Overproduction of prostaglandins have been observed in several conditions, including bladder outlet obstruction ([@B36]), bladder overactivity due to spinal cord injury ([@B37]), and in inflammation ([@B63]). Furthermore, contractions of the detrusor smooth muscle in response to acetylcholine and ATP are enhanced by prostaglandins in both rabbit ([@B5]) and guinea-pig animal models ([@B44]). There are complex interactions between the three chemicals, as ATP enhances PGE~2~ release via a P2-purinoreceptor-mediated mechanism ([@B32]), and acetylcholine is a modulator of PGE~2~ release ([@B45]). The interactions between these mediators can potentially result in amplification of molecule signaling and therefore in increased contractile activity, further supporting the interest in investigating prostaglandin involvement in contractile disorders such as OAB. Other research has also shown interest in prostaglandin release from the lower urinary tract. For example, the presence of PGE~2~ in the urine has been linked to bladder dysfunction and proposed as a potential future biomarker ([@B52]). To further this, urine samples collected from female patients with overactive bladder showed that there were significant increases in the PGE~2~ and PGF~2α~ levels when compared with the control group ([@B33]).

Prostaglandin E~2~, in particular, is thought to be the most likely contributor to bladder disorders as it can modulate bladder function via afferent signaling ([@B6]) and potentially detrusor overactivity by sensitizing capsaicin-sensitive afferent nerve endings ([@B35]; [@B47]). It is released upon degranulation of mast cells ([@B54]) together with histamine, which is also capable of impacting the bladder contractility ([@B58], [@B59]). Moreover, PGE~2~ is produced locally in the bladder in response to distension and inflammation ([@B24]). Notably, the excitatory effects exerted on the bladder wall via the stimulation of PGE~2~ receptors has previously been studied in the rat ([@B14]) and mouse ([@B55]; [@B38]) animal models. There are four identified prostaglandin E~2~ receptor subtypes: EP1, EP2, EP3, and EP4. The presence of the EP1 and EP2 receptor subtypes has been shown in guinea pig urothelium and lamina propria ([@B51]) and the expression of all four PGE~2~ receptor subtypes (EP1--EP4) has been identified in the canine bladder using *in situ* hybridization and immunohistochemistry ([@B49]). Generally, activation of EP1 and EP3 receptors is associated with an excitatory response, whereas EP2 and EP4 are associated with inhibition of smooth muscle contractility ([@B64]). Furthermore, clinical uses of the prostaglandin E~2~ agonist dinoprostone, include the stimulation of uterine smooth muscle contractions during labor ([@B57]) with the prostaglandin F~2α~ agonist, carboprost, being a viable alternative to oxytocin during the management of labor ([@B61]). Therefore, the involvement of EP1, EP3 and FP receptors is of particular interest in the modulation of lower urinary tract contractility due to their excitatory effect when stimulated.

Alterations in bladder physiology in disease states has been thought to primarily occur through the regulation of detrusor smooth muscle contractility. However, it is increasingly recognized that the bladder urothelium with lamina propria (U&LP, also called the bladder mucosa) plays an important role in the overall contractility of the bladder and in its intracellular signaling. As such, recent research has focused on the effects of pharmacological mediators on the physiology of the U&LP and the detrusor as separate layers. This study aimed to compare responses of the urothelium with lamina propria to PGE~2~ with those of the detrusor and identify the receptor subtypes responsible for the PGE~2~-mediated contractions in these tissues.

Materials and Methods {#S2}
=====================

Tissue Preparation {#S2.SS1}
------------------

Urinary bladders were obtained from female Large-White-Landrace pigs (approximately 6 months old, with a live-weight of 80--100 kg) from the local abattoir after slaughter for the routine commercial provision of food. Isolated strips (10 mm × 5 mm) of porcine bladder were removed from the anterior wall of the bladder dome region and urothelium with lamina propria (U&LP) carefully dissected from the underlying detrusor layer. Two adjacent strips were taken from each animal's bladder and paired together as control-experimental tissues, with each paired strip preparation expressed as "*n*" where comparisons or changes are recorded. *n* equates to the number of individual bladders used in this study.

Strips of U&LP and detrusor tissue were suspended in 10 mL organ baths (Labglass, Brisbane, QLD, Australia) containing Krebs-bicarbonate solution (NaCl 118.4 mM, NaHCO~3~ 24.9 mM, CaCl~2~ 1.9 mM, MgSO~4~ 2.41 mM, KCl 4.6 mM, KH~2~PO~4~ 1.18 mM, and [D]{.smallcaps}-glucose 11.7 mM) at 37°C and perfused with a gas mixture of 95% oxygen and 5% carbon dioxide. The preparations were washed three times with Krebs-bicarbonate solution and tension adjusted to approximately 2 g, which then became the tissue baseline. A single dose of agonist was added to the U&LP and detrusor preparations after an incubation period with an antagonist or vehicle control. The concentrations specific for each receptor subtype were determined using affinity values appearing in the literature utilizing similar methodology and isolated tissue bath experiments. Tissue strips exposed to antagonists or vehicle controls were incubated for 30 min to allow full equilibration with the receptor. Each experiment was completed within 20 min after the addition of the agonist. Baseline tension, frequency and amplitude of spontaneous phasic contractions were recorded simultaneously using isometric force transducers (MCT050/D, ADInstruments, Castle Hill, NSW, Australia) on a PowerLab system using LabChart v7 software (ADInstruments). Porcine urinary bladders are a well-recognized animal model for bladder research ([@B12]; [@B48]; [@B40]; [@B58]) with similar physiology and pharmacology to human bladders. As no animals were bred, harmed, culled, interfered, or interacted with as part of this research project, Animal Ethics Approval was not required for bladder use ([@B50]).

Pharmaceutical Agents {#S2.SS2}
---------------------

Prostaglandin E~2~, F~2α~, EP1 receptor antagonist SC-19220, EP1, and EP2 receptor antagonist AH6809, EP3 receptor antagonist L-798106, EP4 receptor antagonist AH23848, FP receptor antagonist AL-8810 and ATP receptor agonist α,β-methylene ATP were obtained from Cayman Chemicals, Ann Arbor, MI, United States. The muscarinic receptor antagonist atropine, cyclooxygenase (COX) inhibitor indomethacin, and the nitric oxide synthase inhibitor N~ω~-Nitro-L-arginine were obtained from Sigma Aldrich, St. Louis, MO, United States. Prostaglandin E~2~, prostaglandin F~2α~, AH6809 and indomethacin were dissolved in 100% ethanol and diluted as needed with distilled H~2~O. Atropine, N~ω~-Nitro-L-arginine, and α,β-methylene ATP were dissolved in distilled H~2~O and diluted as required. SC19220, L-798196, AH23848, and AL-8810 were dissolved in DMSO and diluted with distilled H~2~O.

Experimental Procedure {#S2.SS3}
----------------------

A single dose of prostaglandin E~2~ (1 or 10 μM) or prostaglandin F~2α~ (10 μM) was applied to an isolated strip of U&LP or detrusor after a 30-minute equilibration period with a selective receptor antagonist. Baseline tensions and the amplitude and frequency of spontaneous phasic contractions of U&LP were measured before the application of the agonist and 5 min after addition. As spontaneous contractions were only observed in 21% of detrusor samples, only baseline tension was measured (before the application of the agonist, 10 min after and 20 min after).

Measurements and Statistical Analysis {#S2.SS4}
-------------------------------------

The changes in the baseline tension were measured before the addition of an agonist and at the peak contractile response. The frequency of spontaneous contractions was measured over a period of 5 min and expressed as the number of spontaneous phasic contraction cycles per minute (cpm). The average amplitude was measured from base to peak of each spontaneous contraction. Measurements for frequency and amplitude were taken before any agonist was added and during the peak contractile response to the agonist. Data was graphed and analyzed using GraphPad Prism version 8.1.1 for Windows (GraphPad Software, La Jolla, CA, United States) and results shown as the mean change ± SEM. Responses between control and experimental tissues were compared using a Student's *t*-test with *p* \< 0.05 considered significant.

Results {#S3}
=======

Prostaglandin E~2~ on U&LP Preparations {#S3.SS1}
---------------------------------------

In the absence of prostaglandin E~2~ or any receptor antagonists, strips of urothelium with lamina propria (U&LP) exhibited spontaneous phasic contractions at frequencies of 3.34 ± 0.06 cycles per min^--1^ (cpm) with amplitudes of 0.52 ± 0.02 g (*n* = 215 for both). In response to prostaglandin E~2~ (1 μM), U&LP baseline tensions increased by 91 ± 9% (*n* = 38, *p* \< 0.001), the frequency of spontaneous phasic contractions increased by 39 ± 7% (*n* = 38, *p* \< 0.001) and amplitudes decreased by 18 ± 5% (*n* = 38, *p* \< 0.001) during the peak response ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). The addition of an even higher concentration of prostaglandin E~2~ (10 μM) caused increases in the U&LP baseline tensions by 106 ± 9% (*n* = 42, *p* \< 0.001), frequencies of spontaneous phasic contractions by 40 ± 10% (*n* = 42, *p* \< 0.01) and amplitude decreases by 28 ± 6% (*n* = 22, *p* \< 0.001) during peak response ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

###### 

U&LP effect of prostaglandin E~2~ (1 and 10 μM) on the baseline tension and on the frequency and amplitude of spontaneous phasic contractions (mean change ± SEM).

  PGE~2~ conc.   ΔTension (g)        ΔFrequency (cpm)    ΔAmplitude (g)       *n*
  -------------- ------------------- ------------------- -------------------- -----
  1 μM           1.01 ± 0.08\*\*\*   1.13 ± 0.19\*\*\*   −0.14 ± 0.04\*\*\*   38
  10 μM          1.36 ± 0.09\*\*\*   1.19 ± 0.30\*\*     −0.16 ± 0.03\*\*     42

\*\*

p

\< 0.05, \*\*\*

p

\< 0.001. Paired Student's two-tailed

t

-test.

![Traces showing changes to baseline tension of U&LP in response to PGE~2~ at concentrations of 1 μM **(A)** and 10 μM **(B)** over 15 min. **(C)** Peak responses after the addition of PGE~2~ (1 μM, *n* = 38) and PGE~2~ (10 μM, *n* = 42).](fphys-11-00705-g001){#F1}

Prostaglandin E~2~ on Detrusor Preparations {#S3.SS2}
-------------------------------------------

In detrusor preparations, PGE~2~ caused concentration-dependent increases in baseline tension over the increasing concentrations (1--10 μM, [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Detrusor preparations did not reach a visible peak in response to PGE~2~ within the experimental timeframe, so each tension recording was completed at set intervals of 10 and 20 min. In response to prostaglandin E~2~ (1 μM, [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}), an increase of 80 ± 13% (*n* = 38, *p* \< 0.001) was observed 10 min after the addition of the agonist, and in response to prostaglandin E~2~ (10 μM, [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}) an increase of 155 ± 21% (*n* = 34, *p* \< 0.001) was observed 10 min after the addition of agonist. Twenty minutes after the addition of prostaglandin E~2~ (1 μM, [Table 2](#T2){ref-type="table"}), baseline tensions had increased by 107 ± 13% (*n* = 38, *p* \< 0.001), whereas 20 min after the treatment with prostaglandin E~2~ (10 μM, [Table 2](#T2){ref-type="table"}), had increased by 175 ± 21% (*n* = 34, *p* \< 0.001).

###### 

Detrusor effect of prostaglandin E~2~ (1 and 10 μM) on the baseline tension and on the frequency and amplitude of spontaneous phasic contractions (mean change ± SEM).

  PGE~2~ conc.   ΔTension (g) at 10 min   ΔTension (g) at 20 min   *n*
  -------------- ------------------------ ------------------------ -----
  1 μM           0.77 ± 0.09\*\*\*        1.06 ± 0.09\*\*\*        38
  10 μM          1.34 ± 0.14\*\*\*        1.46 ± 0.11\*\*\*        34

\*\*\*

p

\< 0.001. Paired Student's two-tailed

t

-test.

![Traces showing changes to baseline tension of detrusor smooth muscle in response to PGE~2~ at concentrations of 1 μM **(A)** and 10 μM **(B)** over 15 min. **(C)** Peak responses after the addition of PGE~2~ (1 μM, *n* = 38) and PGE~2~ (10 μM, *n* = 34).](fphys-11-00705-g002){#F2}

Only 21% of all detrusor preparations exhibited spontaneous phasic contractions at baseline and as such, the frequency and amplitude of spontaneous activity was not calculated. Of those that did not exhibit baseline activity, spontaneous phasic contractions were initiated after the addition of PGE~2~ in 83% of preparations.

Receptor-Selective Antagonists in U&LP Preparations {#S3.SS3}
---------------------------------------------------

The responses to prostaglandin E~2~ were observed in the presence of the selective receptor antagonists: SC-19220 (EP1 antagonist, 10 μM), AH6809 (EP1/EP2 antagonist, 10 μM), L-798106 (EP3 antagonist, 100 nM) and AH23848 (EP4 antagonist, 10 μM). None of the prostaglandin E~2~ receptor antagonists had any effect on baseline tension, frequency or amplitude of spontaneous phasic contractions and they also had no effect on U&LP in response to prostaglandin E~2~ (1 μM, [Table 3](#T3){ref-type="table"}). The time required to reach peak baseline tension was investigated in U&LP tissues treated with PGE~2~ in the presence and absence of EP receptor antagonists. In response to prostaglandin E~2~ (1 μM), U&LP tissue strips took 4.48 ± 0.28 min to reach their peak baseline tensions. Tissues incubated with SC-19220 (1 μM, *n* = 8, *p* \< 0.05) took 6.37 ± 0.39 min to reach peak. There were no significant differences in times taken to reach peak baseline tension in tissues treated with either AH6809, L-798106 or AH23848.

###### 

Baseline tension and phasic contraction responses to U&LP treatment with prostaglandin E~2~ (1 μM) in the absence and presence of prostaglandin E~2~ receptor antagonists (mean change ± SEM).

                      ΔTension (g)   ΔFrequency (cpm)                               
  ---------- -------- -------------- ------------------ ------------- ------------- ----
  SC-19220   10 μM    1.01 ± 0.19    1.27 ± 0.24        1.32 ± 0.43   1.88 ± 0.38   8
  AH6809     10 μM    1.12 ± 0.19    1.14 ± 0.20        1.42 ± 0.53   1.23 ± 0.41   8
  L-798106   100 nM   0.97 ± 0.09    0.82 ± 0.10        0.68 ± 0.15   0.80 ± 0.18   8
  AH23848    10 μM    0.90 ± 0.10    0.99 ± 0.13        1.05 ± 0.36   1.61 ± 0.44   12

None of the antagonists had statistically significant effects using a paired Student's two-tailed

t

-test.

The potential influence of receptor systems, other than prostaglandin E~2~, to contribute contractile responses to PGE~2~ were investigated. Neither the baseline tension, frequency nor amplitude of spontaneous phasic contractions in response to prostaglandin E~2~ (10 μM) were affected by the presence of the muscarinic receptor antagonist atropine (1 μM), cyclooxygenase (COX) inhibitor indomethacin (5 μM), nitric oxide synthase inhibitor N~ω~-Nitro-L-arginine (L-NNA, 100 μM) or P2X receptor desensitizing agonist α,β-methylene ATP (αβm-ATP, 10 μM, [Table 4](#T4){ref-type="table"}). The tissue did not exhibit changes in the tension or in the frequency of phasic contractions in response to the addition of the FP receptor antagonist AL-8810 (5 μM). However, the presence of AL-8810 (5 μM) significantly inhibited increases in the baseline tension in response to PGE~2~ (10 μM, *n* = 8, *p* \< 0.05, [Figure 3](#F3){ref-type="fig"}). In the absence of any antagonist, contractions to PGE~2~ increased the tension by 103 ± 12%. In the presence of AL-8810 (5 μM) this increase was inhibited with the remaining contraction being 77 ± 8% (*n* = 8, *p* \< 0.05, [Table 4](#T4){ref-type="table"}).

###### 

U&LP responses to prostaglandin E~2~ (10 μM) in the absence and presence of atropine (muscarinic antagonist), indomethacin (cyclooxygenase antagonist), N~ω~-Nitro-L-arginine (L-NNA, nitric oxide antagonist), α,β-methylene ATP (αβm-ATP, ATP agonist), and AL-8810 (FP antagonist) (mean change ± SEM).

                          ΔTension (g)   ΔFrequency (cpm)                               
  -------------- -------- -------------- ------------------ ------------- ------------- ---
  Atropine       1 μM     1.45 ± 0.18    1.55 ± 0.12        0.53 ± 0.18   0.86 ± 0.21   6
  Indomethacin   5 μM     1.90 ± 0.25    1.79 ± 0.21        0.73 ± 1.29   2.11 ± 1.45   4
  L-NNA          100 μM   2.00 ± 0.32    2.31 ± 0.42        2.86 ± 1.32   3.51 ± 1.78   4
  αβm-ATP        10 μM    1.58 ± 0.35    1.99 ± 0.48        0.46 ± 0.22   0.49 ± 0.23   4
  AL-8810        5 μM     1.35 ± 0.13    0.93 ± 0.14\*      1.12 ± 0.38   0.68 ± 0.27   8

\*

p

\< 0.05. Paired Student's two-tailed

t

-test.

![U&LP responses to PGE~2~ (10 μM) **(A)** and in the presence of FP receptor antagonist AL-8810 (5 μM) **(B)**. Increases in the baseline tension in response to PGE~2~ are represented as mean change ± SEM **(*C*)**. Changes in the baseline tension between control and experimental conditions were evaluated using a paired Student's two tailed *t*-test, where \**p* \< 0.05.](fphys-11-00705-g003){#F3}

Receptor-Selective Antagonists in Detrusor Preparations {#S3.SS4}
-------------------------------------------------------

Detrusor preparations did not reach a visible peak in response to PGE~2~ (1 μM) within the experimental timeframe, so each tension recording was completed at set intervals of 10 and 20 min. As such, changes in detrusor tension were measured at 10 and 20 min after the addition of each agonist ([Table 5](#T5){ref-type="table"}). The responses to prostaglandin E~2~ were observed in the presence of the selective prostaglandin E~2~ receptor antagonists: SC-19220 (EP1 antagonist, 10 μM), AH6809 (EP1/EP2 antagonist, 10 μM), L-798106 (EP3 antagonist, 100 nM) and AH23848 (EP4 antagonist, 10 μM). None of the prostaglandin E~2~ receptor antagonists had any effect on baseline tension in detrusor tissue strips in response to prostaglandin E~2~ (1 μM).

###### 

Detrusor responses to prostaglandin E~2~ (1 μM) at 10 and 20 min after the addition of agonist in the absence and presence of PGE~2~ receptor antagonists (mean change ± SEM).

                      ΔTension (g) at 10 min   ΔTension (g) at 20 min                               
  ---------- -------- ------------------------ ------------------------ ------------- ------------- ----
  SC-19220   10 μM    0.60 ± 0.08              0.49 ± 0.11              1.12 ± 0.18   1.09 ± 0.15   8
  AH6809     10 μM    0.64 ± 0.13              0.62 ± 0.10              0.96 ± 0.16   0.95 ± 0.16   8
  L-798106   100 nM   1.12 ± 0.20              1.05 ± 1.16              1.25 ± 0.20   1.35 ± 0.26   10
  AH23848    10 μM    0.46 ± 0.10              0.49 ± 0.14              0.81 ± 0.16   0.80 ± 0.16   8

None of the antagonists had statistically significant effects (paired Student's two-tailed

t

-test).

The potential for receptor systems, other than prostaglandin E~2~, to contribute contractile responses to PGE~2~ were investigated. It was found that the baseline tension in detrusor preparations, in response to prostaglandin E~2~ (10 μM), was not affected by the presence of the muscarinic receptor antagonist atropine (1 μM), cyclooxygenase (COX) inhibitor indomethacin (5 μM), nitric oxide synthase inhibitor N~ω~-Nitro-L-arginine (L-NNA, 100 μM) or P2X receptor desensitizing agonist α,β-methylene ATP (αβm-ATP, 10 μM, [Table 6](#T6){ref-type="table"}). Treatment with the FP receptor antagonist AL-8810 (5 μM) did not affect baseline responses. In the presence of AL-8810 increases to baseline tension mediated by prostaglandin E~2~ (10 μM) were significantly inhibited both 10 and 20 min after the addition of the agonist (*n* = 8, *p* \< 0.05 for both, [Figure 4](#F4){ref-type="fig"}). In the absence of any antagonists, contractions to PGE2 increased the tension by 233 ± 60% at 10 min. In the presence of AL-8810 (5 μM) this increase was inhibited with the remaining contraction of 127 ± 46% (*n* = 8, *p* \< 0.05, [Table 6](#T6){ref-type="table"}).

###### 

Detrusor responses to prostaglandin E~2~ (10 μM) in the absence and presence of atropine (muscarinic antagonist), indomethacin (cyclooxygenase antagonist), N~ω~-Nitro-L-arginine (L-NNA, nitric oxide antagonist), α,β-methylene ATP (αβm-ATP, ATP agonist), and AL-8810 (FP antagonist) (mean change ± SEM).

                          ΔTension (g) at 10 min   ΔTension (g) at 20 min                                 
  -------------- -------- ------------------------ ------------------------ ------------- --------------- ---
  Atropine       1 μM     1.38 ± 0.21              1.02 ± 0.09              1.72 ± 0.11   1.47 ± 0.11     6
  Indomethacin   5 μM     1.55 ± 0.55              1.29 ± 0.42              1.75 ± 0.55   1.35 ± 0.43     4
  L-NNA          100 μM   2.21 ± 0.28              1.90 ± 0.32              2.05 ± 0.26   1.94 ± 0.27     4
  αβm-ATP        10 μM    1.40 ± 0.21              1.72 ± 0.49              1.45 ± 0.29   1.94 ± 0.43     4
  AL-8810        5 μM     1.43 ± 0.36              0.84 ± 0.21\*            1.39 ± 0.22   1.01 ± 0.18\*   8

\*

p

\< 0.05. Paired Student's two-tailed

t

-test.

![Detrusor responses to PGE~2~ (10 μM) **(A)** and in the presence of FP receptor antagonist AL-8810 (5 μM) **(B)**. Increases in the baseline tension in response to PGE~2~ are represented as mean change ± SEM **(C)**. Changes in the baseline tension between control and experimental conditions were evaluated using a paired Student's two tailed *t*-test, where \**p* \< 0.05.](fphys-11-00705-g004){#F4}

Prostaglandin F~2α~ on U&LP and Detrusor Preparations {#S3.SS5}
-----------------------------------------------------

In preparations of U&LP, treatment with PGF~2α~ (10 μM) caused a significant increase in the baseline tension of 65 ± 9% (*n* = 14, *p* \< 0.001). Additionally, the frequency of spontaneous phasic contractions increased by 13 ± 5% (*n* = 14, *p* \< 0.05) with no changes observed in the amplitude of these contractions. In the presence of AL-8810 (FP antagonist, 5 μM), increases in the baseline tension in response to PGF~2α~ (10 μM) were significantly inhibited (*n* = 8, *p* \< 0.001, [Table 7](#T7){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}). However, the antagonism of FP receptor did not affect the frequency or amplitude of spontaneous phasic contractions.

###### 

U&LP responses to PGF~2α~ (10 μM) in the absence and presence of AL-8810 on the baseline tension and on the frequency and amplitude of phasic contractions (top).

                                                                               PGF~2α~ with     
  --------------------------------------- ------------------------ ----------- ---------------- ---
  Urothelium with lamina propria (U&LP)   ΔTension (g)             0.850.09    0.490.08\*\*\*   8
                                          ΔAmplitude (g)           −0.110.06   −0.130.07        8
                                          ΔFrequency (cpm)         0.670.23    0.730.14         8
  Detrusor                                ΔTension (g) at 10 min   0.780.18    0.360.04\*       8
                                          ΔTension (g) at 20 min   0.910.19    0.570.08         8

Detrusor baseline tension responses at 10 and 20 min to PGF

2

α

(10 μM) in the absence and presence of AL-8810 (bottom). Results represented as mean change ± SEM. \*

p

\< 0.05, \*\*\*

p

\< 0.001. Paired Student's two-tailed

t

-test.

![U&LP and detrusor responses to PGF~2α~ (10 μM) **(A)** and in the presence of FP receptor antagonist AL-8810 (5 μM) **(B)**. Increases in the baseline tension in response to PGF~2α~ are represented as mean change ± SEM **(C)**. Changes in the baseline tension between control and experimental conditions were evaluated using a paired Student's two tailed *t*-test, where \**p* \< 0.05, \*\*\**p* \< 0.001.](fphys-11-00705-g005){#F5}

In detrusor preparations, an increase of 88 ± 10% (*n* = 12, *p* \< 0.001) was observed in response to PGF~2α~ (10 μM). The presence of FP antagonist AL-8810 (5 μM) significantly inhibited increases in the baseline tension (*n* = 8, *p* \< 0.05). The inhibition was maintained both 10 and 20 min after the addition of PGF~2α~ (10 μM, [Table 7](#T7){ref-type="table"}).

Discussion {#S4}
==========

This study presents prostaglandin E~2~ as a potential contributor to the overall urinary bladder contractility and showcases the ability of isolated urothelium with lamina propria (also called the bladder mucosa) to respond to this inflammatory mediator. Prostaglandin E~2~ causes a baseline tension increase in both U&LP and detrusor tissue, as well as influences the frequency and amplitude of U&LP spontaneous phasic contractions. In addition, this study is the first to identify responses to PGE~2~ in the urothelium with lamina propria when separated from its underlying detrusor layer. The two layers are distinct in both structure and function, with the U&LP comprized of several layers of epithelial cells and an underlying connective tissue layer with muscularis mucosae, while the detrusor is composed primarily of smooth muscle cells. The U&LP not only provides a physical barrier between urine and the bladder wall but is also capable of releasing chemicals like acetylcholine which can influence the contractility of the detrusor ([@B43]). Furthermore, it is also capable of responding to external signals like noradrenaline ([@B42]), nitric oxide ([@B41]), the five primary prostaglandins ([@B60]), and histamine ([@B58], [@B59]), as well as release ATP ([@B8]). It is known that cells found in U&LP can express both EP1 and EP2 receptors ([@B51]) indicating that they are capable of responding to PGE~2~ and eliciting a contractile response. However, the exact mechanisms and the involvement of the different PGE~2~ receptor subtypes in the contractile responses observed are still unclear.

In this study, increases in the baseline tension in both U&LP and detrusor tissues that were treated with two concentrations of PGE~2~ (1--10 μM) were observed. The presence of PGE~2~ increased the frequency of spontaneous contractile activity, which was similar to responses after muscarinic receptor activation ([@B43]), the target of many first-line pharmaceuticals to treat overactive bladder. In detrusor preparations, which generally do not exhibit spontaneous phasic contractions, these contractions were initiated in most preparations in response to the addition of PGE~2~. Previous studies have shown that contractions in detrusor smooth muscle in response to acetylcholine and ATP are enhanced by the presence of prostaglandins in both rabbit ([@B5]) and guinea-pig animal models ([@B45]). There are complex interactions between these three molecules, as ATP enhances PGE~2~ release via a P2-purinoreceptor-mediated mechanism ([@B32]) and acetylcholine release has been detected when unstretched preparations were exposed to PGE~2~ ([@B45]). Thereby, interactions between these three mediators can potentially result in the amplification of molecule signaling and an increase in contractile activity. However, the involvement of acetylcholine, ATP and nitric oxide in mediating the increases in both the baseline tension and the frequency of spontaneous phasic contractions were ruled out as the contractile responses were the same when respective receptors were selectively antagonized or desensitized. Therefore, even though previous research has shown that acetylcholine is released when tissue is exposed to PGE~2~ ([@B45]), the inhibition of muscarinic receptors revealed no changes in the magnitude of contractions in response to PGE~2~. Furthermore, treatment with indomethacin, which inhibits prostaglandin production via cyclooxygenase (COX), did not affect contractile responses.

In order to isolate the role of a specific PGE~2~ receptor subtype in mediating these changes to baseline tension and the frequency of spontaneous phasic contractions, selective receptor antagonists for EP1--EP4 receptors were used. The antagonists and concentrations selected for this study were based on prior research investigating smooth muscle contractility in rat prostate gland ([@B62]). When U&LP and detrusor smooth muscle tissues were treated with each individual PGE~2~ receptor subtype antagonists (EP1--EP4), there were no differences observed in the contractile responses to PGE~2~ when compared to tissues with no antagonist treatment. Activation of EP1 and EP3 receptor subtypes mediate contractions in smooth muscle, whereas EP2 and EP4 are involved in the relaxatory responses ([@B64]). In this study, when both U&LP and detrusor tissues were treated with the highly selective EP1 receptor antagonist SC19220 with a pA~2~ value of approximately 5.9 ([@B30]) and EP3 receptor antagonist L798106 with a K*i* of 0.3 nM ([@B31]) there was no change in the magnitude of contractions to PGE~2~. However, when U&LP was incubated with the EP1-selective receptor antagonist SC-19220, it took significantly more time to reach peak contraction in response to PGE~2~ compared to control tissues. Even though the stimulation of EP2 receptors has previously been shown to relax non-vascular urogenital smooth muscle tissue ([@B16]; [@B62]), no changes in contractile response were observed in tissue preparations that were treated with the dual EP1 and EP2 antagonist AH6809 \[pA for EP1 approximately 7.3 and pA~2~ for EP2 approximately 5.7 ([@B30])\]. The involvement of EP4 receptors in the inhibition of muscle contractions was also ruled out using AH23848, an antagonist for EP4 receptors (pA~2~ value 5.4) with no activity on other EP receptor subtypes ([@B16]). The lack of responses also aligns with previous findings suggesting that the EP4 receptor is involved in vascular smooth muscle relaxation instead of smooth muscle of the urinary bladder ([@B16]; [@B62]). Findings of this study suggest that the contractile responses observed to prostaglandin E~2~ in both U&LP and detrusor may be mediated by receptors systems other than EP, purinergic and cholinergic.

The ability of AL-8810 to significantly inhibit the contractile response to PGE~2~ suggests a mechanism of action at the FP receptor. This is most likely a result of the PGE~2~ chemical undergoing a conversion from PGE~2~ into PGF~2α~ through 9-ketoreductase activity upon contact with the tissue. The potential for these conversions has been known for some time ([@B11]; [@B13]; [@B1]). There is evidence to support a partial agonist effect of AL-8810 ([@B25]). Although the addition of this antagonist showed no response, or any effect on the baseline activity. The contraction remaining after FP receptor inhibition is unknown, although does not appear to be related to stimulation of the muscarinic, purinergic or nitric oxide receptor systems, nor from the creation of new prostaglandins. One potential mechanism of action could be via a receptor unspecific pathway, such as affecting calcium channels, and this could be considered for future experiments.

A limitation of this study was the use of single-dose applications of PGE~2~ and PGF~2α~ to examine changes in frequencies and amplitudes of phasic contractions over a 20-minute timeframe. It would be of interest to examine a larger range of concentrations, as well as incorporate alternative agonists to obtain a wider understanding of the prostaglandin responses. Finally, there remains no literature showing FP receptor expression or localization in porcine or any other animal model bladders, and its identification throughout this region would assist in a better understanding of this receptor system. It should also be considered that PGE~2~ exhibits a similar affinity to PGF~2α~ on the FP receptor ([@B2]), and as such, there is the potential for an influence of FP receptors in the responses observed. This cross-sensitivity of FP receptors to PGE~2~ may also present a mechanism underlying the inhibitory effect observed from treatment with AL-8810 and should be further explored in follow-up studies. Future studies could also investigate whether the suppressed responses observed after AL-8810 treatment is due to the actions of PGE~2~ after a possible conversion to PGF~2α~.

This study identifies a functional response in both U&LP and detrusor preparations to PGE~2~, and its ability to be inhibited by an FP receptor antagonist suggests some conversion to PGF~2α~ upon contact with the tissue. The response of direct application of PGF~2α~ which appears to be similar to the PGE~2~ response also supports this hypothesis. Thereby, the finding of this study supports and further advances prior research, where PGE~2~ and PGF~2α~ had previously been found to contract isolated detrusor smooth muscle in human preparations ([@B3]; [@B7]; [@B46]).

Conclusion {#S5}
==========

Prostaglandin E~2~ and prostaglandin F~2α~ can elicit clear contractile responses in both urinary bladder urothelium with lamina propria, and detrusor smooth muscle preparations. Furthermore, the addition of these prostaglandins in U&LP preparations increases the frequency of spontaneous phasic contractions. In the detrusor, which normally does not exhibit spontaneous contractions, these contractions were initiated in most preparations. The antagonism of all four PGE~2~ receptor subtypes, cholinergic receptors and purinergic receptors failed to inhibit contractile responses observed to the prostaglandins in either U&LP or detrusor tissues. However, the inhibition of EP1 receptor in U&LP resulted in a significant decrease in the time taken to reach peak contractile responses to PGE~2~ suggesting partial mediation via the EP1 receptor system. Antagonism of the FP receptor inhibited responses to PGF~2α~, but also to PGE~2~, suggesting some conversion of this into PGF~2α~ after contact with the tissue. Overall, contractile responses to both prostaglandin E~2~ and prostaglandin F~2α~ appear mediated, in part, by the FP receptor in both U&LP and detrusor smooth muscle.
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ATP

:   adenosine triphosphate

OAB

:   overactive bladder

PGE~2~

:   prostaglandin E~2~

PGF~2\ α~

:   prostaglandin F~2\ α~

SEM

:   standard error of the mean

U&LP

:   lamina propria with urothelium

UAB

:   underactive bladder

αβ m-ATP

:   α β− methylene ATP.
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